The PD-L1 inhibitor pembrolizumab (MK-3475) is being evaluated in a clinical trial of patients with recurrent IDH1-mutant grade II–IV gliomas whose tumours have a hypermutator phenotype (NCT02658279). The gene discussed is CD274; the disease is central nervous system cancer.